Literature DB >> 23711243

Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo.

S You1, Y-H Cho, J-S Byun, E-C Shin.   

Abstract

In the present study, we established a novel murine model of vitiligo by sequential prime/boost immunizations into the hind footpad and tail dermis with tyrosinase-related protein 2 (TRP2)-180 (SVYDFFVWL) peptide, lipopolysaccharides and cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides. Immunized mice developed epidermal depigmentation in the tail skin without hair depigmentation, thereby differentiating this approach from established models of vitiligo. Following intradermal tail immunization, activated CD8(+) interferon (IFN)-γ(+) T cells were recruited locally to the tail skin. In-vivo cytotoxicity assays demonstrated specific lysis of TRP2-180-presenting cells in immunized mice. Furthermore, the extent of skin depigmentation correlated with the frequency of TRP2-180-specific splenic CD8(+) T cells, as determined by IFN-γ and tumour necrosis factor (TNF)-α production, and cytotoxic degranulation evidenced by CD107a staining. These findings suggest a correlation between the presence of TRP2-180-specific CD8(+) effector T cells and the development of depigmented skin lesions in our vitiligo model. This new model of vitiligo, characterized by skin depigmentation without hair depigmentation, is more similar to human disease than previous murine models. Therefore, this model is well suited to future studies on the pathogenesis of vitiligo and the development of novel therapeutics for vitiligo.
© 2013 British Society for Immunology.

Entities:  

Keywords:  autoreactive CD8+ T cell; epidermal depigmentation; mouse model; vitiligo

Mesh:

Substances:

Year:  2013        PMID: 23711243      PMCID: PMC3784211          DOI: 10.1111/cei.12146

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.

Authors:  K S Lang; C C Caroli; A Muhm; D Wernet; A Moris; B Schittek; E Knauss-Scherwitz; S Stevanovic; H G Rammensee; C Garbe
Journal:  J Invest Dermatol       Date:  2001-06       Impact factor: 8.551

Review 2.  A 'hairy' privilege.

Authors:  Ralf Paus; Brian J Nickoloff; Taisuke Ito
Journal:  Trends Immunol       Date:  2005-01       Impact factor: 16.687

3.  Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.

Authors:  Jasper G van den Boorn; Debby Konijnenberg; Trees A M Dellemijn; J P Wietze van der Veen; Jan D Bos; Cornelis J M Melief; Florry A Vyth-Dreese; Rosalie M Luiten
Journal:  J Invest Dermatol       Date:  2009-02-26       Impact factor: 8.551

4.  Single hair grafting for the treatment of vitiligo.

Authors:  G Y Na; S K Seo; S K Choi
Journal:  J Am Acad Dermatol       Date:  1998-04       Impact factor: 11.527

5.  Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.

Authors:  Julia Steitz; Jürgen Brück; Julia Lenz; Steffi Büchs; Thomas Tüting
Journal:  J Invest Dermatol       Date:  2005-01       Impact factor: 8.551

6.  Role of hair follicles in the repigmentation of vitiligo.

Authors:  J Cui; L Y Shen; G C Wang
Journal:  J Invest Dermatol       Date:  1991-09       Impact factor: 8.551

7.  Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.

Authors:  B Palermo; R Campanelli; S Garbelli; S Mantovani; E Lantelme; V Brazzelli; M Ardigó; G Borroni; M Martinetti; C Badulli; A Necker; C Giachino
Journal:  J Invest Dermatol       Date:  2001-08       Impact factor: 8.551

8.  Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.

Authors:  Rochelle L Mandelcorn-Monson; Neil H Shear; Eddy Yau; Suryaprakash Sambhara; Brian H Barber; David Spaner; Mark A DeBenedette
Journal:  J Invest Dermatol       Date:  2003-09       Impact factor: 8.551

9.  Vitiligo and the melanocyte reservoir.

Authors:  Rafael Falabella
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

10.  Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Authors:  Randal K Gregg; Lisa Nichols; Yiming Chen; Bao Lu; Victor H Engelhard
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

View more
  4 in total

Review 1.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 2.  The role of IL-17 in vitiligo: A review.

Authors:  Rasnik K Singh; Kristina M Lee; Ivan Vujkovic-Cvijin; Derya Ucmak; Benjamin Farahnik; Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Tina Bhutani; Maria Wei; Wilson Liao
Journal:  Autoimmun Rev       Date:  2016-01-21       Impact factor: 9.754

3.  Priming of autoreactive CD8(+) T cells is inhibited by immunogenic peptides which are competitive for major histocompatibility complex class I binding.

Authors:  Sooseong You; Yoon Seok Choi; Seokchan Hong; Eui-Cheol Shin
Journal:  Immune Netw       Date:  2013-06-30       Impact factor: 6.303

4.  Potential Role of Chronic Physical Exercise as a Treatment in the Development of Vitiligo.

Authors:  Elias de França; Ronaldo V T Dos Santos; Liliana C Baptista; Marco A R Da Silva; André R Fukushima; Vinícius B Hirota; Raul A Martins; Erico C Caperuto
Journal:  Front Physiol       Date:  2022-03-10       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.